|
1
|
El Armouche A and Eschenhagen T:
β-Adrenergic stimulation and myocardial function in the failing
heart. Heart Fail Rev. 14:225–241. 2009.
|
|
2
|
Cohn JN, Levine TB and Olivari MT: Plasma
norepinephrine as a guide to prognosis in patients with chronic
congestive heart failure. N Engl J Med. 311:819–823. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Triposkiadis F, Karayannis G, Giamouzis G,
Skoularigis J, Louridas G and Butler J: The sympathetic nervous
system in heart failure physiology, pathophysiology, and clinical
implications. J Am Coll Cardiol. 54:1747–1762. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liggett SB, Mialet-Perez J, Thaneemit-Chen
S, et al: A polymorphism within a conserved beta(1)-adrenergic
receptor motif alters cardiac function and betablocker response in
human heart failure. Proc Natl Acad Sci USA. 103:11288–11293. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
McNamara DM: Emerging role of
pharmacogenomics in heart failure. Curr Opin Cardiol. 23:261–268.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lang RM, Bierig M, Devereux RB, et al:
Recommendations of chamber quantification. Eur J Echocardiogr.
7:79–108. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
De Groote P, Lamblin N, Helbecque N, et
al: The impact of beta-adrenoreceptor gene polymorphisms on
survival in patients with congestive heart failure. Eur J Heart
Fail. 7:966–973. 2005.PubMed/NCBI
|
|
8
|
Maqbool A, Hall A, Ball S and Balmforth
AJ: Common polymorphisms of beta1-adrenoceptor: identification and
rapid screening assay. Lancet. 353:8971999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xie HG, Dishy V, Sofowora G, et al:
Arg389Gly beta 1-adrenoceptor polymorphism varies in frequency
among different ethnic groups but does not alter response in vivo.
Pharmacogenetics. 11:191–197. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Moore JD, Mason DA, Green SA, Hsu J and
Liggett SB: Racial differences in the frequencies of cardiac
beta(1)-adrenergic receptor polymorphisms: analysis of c145A>G
and c1165G>C. Hum Mutat. 14:2711999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Small KM, McGraw DW and Liggett SB:
Pharmacology and physiology of human adrenergic receptor
polymorphisms. Annu Rev Pharmacol Toxicol. 43:381–411. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Small KM, Wagoner LE, Levin AM, Kardia SL
and Liggett SB: Synergistic polymorphisms of β1- and α2C-adrenergic
receptors and the risk of congestive heart failure. N Engl J Med.
347:1135–1142. 2002.
|
|
13
|
Tesson F, Charron P, Peuchmaurd M, et al:
Characterization of a unique genetic variant in the
beta1-adrenoceptor gene and evaluation of its role in idiopathic
dilated cardiomyopathy. Cardigene Group. J Mol Cell Cardiol.
31:1025–1032. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Börjesson M, Magnusson Y, Hjalmarson A and
Andersson B: A novel polymorphism in the gene coding for the
beta(1)-adrenergic receptor associated with survival in patients
with heart failure. Eur Heart J. 21:1853–1858. 2000.PubMed/NCBI
|
|
15
|
Podlowski S, Wenzel K, Luther HP, et al:
Beta1-adrenoceptor gen variations: a role in idiopathic dilated
cardiomyopathy? J Mol Med. 78:87–93. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liggett SB, Wagoner LE, Craft LL, Hornung
RW, Hoit BD, McIntosh TC and Walsh RA: The Ile164 beta2-adrenergic
receptor polymorphism adversely affects the outcome of congestive
heart failure. J Clin Invest. 102:1534–1539. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Forleo C, Resta N, Sorrentino S, et al:
Association of β-adrenergic receptor polymorphisms and progression
of heart failure in patients with idiopathic dilated
cardiomyopathy. Am J Med. 117:451–458. 2004.
|
|
18
|
Moraga F, Troncoso R, Mellado R, et al:
Interactions between beta1 and beta2 adrenergic receptor
polymorphisms as risk factors for chronic heart failure. Rev Med
Chil. 136:1371–1380. 2008.(In Spanish).
|
|
19
|
Bray MS, Krushkal J, Li L, et al:
Positional genomic analysis identifies the beta(2)-adrenergic
receptor gen as a susceptibility locus for human hypertension.
Circulation. 101:2877–2882. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Terra SG, Hamilton KK, Pauly DF, et al:
β1-Adenergic receptor polymorphisms and left ventricular remodeling
changes in response to β-blocker therapy. Pharmacogenet Genomics.
15:227–234. 2005.
|
|
21
|
White HL, de Boer RA, Maqbool A, et al: An
evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism
in individuals with heart failure: a MERIT-HF sub-study. Eur J
Heart Fail. 5:463–468. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Magnusson Y, Levin MC, Eggertsen R,
Nyström E, Mobini R, Schaufelberger M and Andersson B: Ser49Gly of
β1-adrenergic receptor is associated with effective β-blocker dose
in dilated cardiomyopathy. Clin Pharmacol Ther. 78:221–231.
2005.
|
|
23
|
Latado AL, Lopes MB, Passos LC and Lopes
AA: Does any evidence exist to treat heart failure based on race or
ethnicity? Rev Assoc Med Bras. 55:110–116. 2009.(In
Portuguese).
|
|
24
|
McNamara DM, Tam W, Sabolisnski ML, et al:
Endothelial nitric oxide synthase (NOS3) polymorphisms in African
Americans with heart failure: results from the A-HeFT trial. J Card
Fail. 15:191–198. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Beta-Blocker Evaluation of Survival Trial
Investigators. A trial of the beta-blocker bucindolol in patients
with advanced chronic heart failure. N Engl J Med. 344:1659–1667.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cohn JN, Fowler MB, Bristow MR, et al:
Safety and efficacy of carvedilol in severe heart failure. The US
Carvedilol Heart Failure Study Group. J Card Fail. 3:173–179. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Packer M, Fowler MB, Roecker EB, et al:
Effect of carvedilol on the morbidity of patients with severe
chronic heart failure: results of the carvedilol prospective
randomized cumulative survival (COPERNICUS) study. Circulation.
106:2194–2199. 2002. View Article : Google Scholar
|
|
28
|
Yancy CW, Laskar S and Eichhorn E: The use
of beta-adrenergic receptor antagonists in the treatment of African
Americans with heart failure. Congest Heart Fail. 10:34–37. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
López-Sendón J, Swedberg K, McMurray J, et
al: Expert consensus document on beta-adrenergic receptor blockers.
Eur Heart J. 25:1341–1362. 2004.PubMed/NCBI
|
|
30
|
Wood AJ: Racial differences in the
response to drugs-pointers to genetic differences. N Engl J Med.
344:1394–1396. 2001. View Article : Google Scholar : PubMed/NCBI
|
